Eleanor N. Fish

PhD, FAAS

Dr. Fish received her B.Sc. from the University of Manchester, UK, her M.Phil. from King’s College, University of London, UK and her Ph.D. from the Institute of Medical Science at the University of Toronto, Canada. Dr. Fish studies the interactions of cytokines, specifically interferons and chemokines, with their receptors in normal and diseased tissues and cells. A focus of Dr. Fish’s research is the investigation of host-pathogen interactions at the cellular and molecular level, specifically in the context of viruses and interferons. During the 2003 outbreak of SARS in Toronto, she initiated studies to investigate the therapeutic potential of interferon in SARS patients. Encouraging results have directed her group’s efforts toward examining type I interferons’ activities against a number of emerging infectious diseases, such as avian H5N1 and pandemic H1N1 influenza viruses. During the ebola virus outbreak in West Africa in 2013-2016, her studies focused on investigating the therapeutic effectiveness of interferon treatment for Ebola virus disease, with a clinical trial in Guinea, with positive outcomes. Dr. Fish was a member of a WHO Working Group to evaluate the therapeutic effectiveness of different antiviral interventions against Ebola virus.  Most recently, in an exploratory clinical study in Wuhan, China, she evaluated the therapeutic effectiveness of IFN-a treatment for COVID-19.


All Sessions by Eleanor N. Fish

Printer Friendly See Full Agenda

Day 1: Jan 26, 2021

11:05 am

11:05 am

KEYNOTE FIRESIDE CHAT

The New Normal for Pharma Marketing: Comprehending the Impact of COVID and What’s Next

The pandemic has had a massive impact on everyone and the pharma industry is looking for answers. When is COVID-19 going away? What does the future pharma organization look like? How do you leverage technology to make sales and marketing more effective? Gain the expert insights you need to move your organization from “stand by” to “new normal” including:

  • Analyzing the rise of telemedicine and drive in medical labs and other fundamental changes to HCPs’ practices
  • Evaluating the changing roles of the pharmacists and nurses under COVID-19
  • Anticipating diagnosis reckonings post-COVID-19: which pharmaceutical products will be more in demand in the coming year
  • Assessing supply chain issues: what is the impact of COVID-19 on the manufacturing of products, equipment and medical supplies?

Amplify your understanding of the effects of COVID-19 on pharma to help you structure your organization for success.

Day 2: Jan 27, 2021

​ ​ ​

Next Speaker